Allied Journal of Medical Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Short Communication - Allied Journal of Medical Research (2023) Volume 7, Issue 1

Healthcare is transformed by personalized medicine. The future of customized medical therapy

Joy Tsuneya*

Department of Pharmacy, School of Health Sciences, University of Patras, GR-26504, Greece

*Corresponding Author:
Mbamalu ON
Department of Pharmacy
School of Health Sciences
University of Patras, GR-26504, Greece

Received: 26-Dec-2022, Manuscript No. AAAJMR-23-85405; Editor assigned: 29-Dec-2022, PreQC No. AAAJMR-23-85405(PQ); Reviewed: 12-Jan-2023, QC No AAAJMR-23-85405; Revised: 17-Jan-2023, Manuscript No. AAAJMR-23-85405(R); Published: 24-Jan-2023, DOI:10.35841/aaajmr-7.1.161

Citation: Tsuneya J. Healthcare is transformed by personalized medicine: The future of customized medical therapy. Allied J Med Res. 2023;7(1):161

Visit for more related articles at Allied Journal of Medical Research


Personalized medicine (PM) focuses on creating a treatment that is as unique as the patient's illness. The strategy depends on locating genetic, epigenomic, and clinical data that enables advancements in our comprehension of how a person's particular genomic portfolio renders them susceptible to specific diseases. The PM technique is a full extension of the old approach to improve our capacity to anticipate which medical therapies, based on the patient's particular genetic profile, will be safe and effective for them and which ones will not. The use of PM has the potential to improve patient quality of life and lengthen patients' lives while requiring less money and time.


Personalized medicine, Healthcare, Hereditary susceptibilities.


The idea of "Personalised" treatment is surrounded by a lot of hype. The foundation of personalized medicine is the idea that since each person has distinct qualities at the molecular, physiological, environmental, and behavioural levels; they may require interventions for diseases they have that are catered to these distinctive characteristics. Through the use of cutting-edge technology, such as DNA sequencing, proteomics, imaging methods, and wireless health monitoring devices, which have shown significant inter-individual diversity in disease processes, this assumption has been partially confirmed [1].

There is a lot of inter-individual variation with regard to the effects of, and mechanisms and factors that contribute to, disease processes, according to the use of emerging, highthroughput, data-intensive biomedical assays like DNA sequencing, proteomics, imaging protocols, and wireless monitoring devices. This has led to concerns about the extent to which judgements regarding the best method to treat, monitor, or prevent a disease for an individual should take into account this inter-individual heterogeneity [2].

Personalized medicines come with a lot of difficulties, particularly when it comes to getting regulatory agency approval for normal usage. The widespread acceptance of personalised pharmaceuticals by various stakeholders in the healthcare industry, including doctors, executives in the industry, insurance companies, and eventually patients, has also raised a number of problems. Many tailored or personalised therapies, such as autologous CAR-T cell transplant therapies for specific types of cancer and mutation-specific medications, such as ivacaftor to treat cystic fibrosis, can be very expensive. As a result, there is a need to demonstrate that personalised medicine strategies simply outperform traditional medicine strategies [3].

PM is regarded as an innovation in the healthcare field because it is proactive, coordinated, and tested. Consumers and stakeholders in the present healthcare system still do not completely understand the advantages of PM. According to recent studies, PM development is hampered by the following factors: The following issues must be addressed: scientific difficulties (genetic markers are the most clinically significant, and we currently have a poor understanding of the molecular mechanisms underlying a number of diseases); economic difficulties; operational difficulties (it is challenging to identify technology and operational procedures that will reduce costs); and protection of personal data during the investigation and development phases. The relationship between government research and regulatory agencies also faces policy problems [4].

PM offers a proven, preventive, and coordinated structural strategy for effective healthcare. It is optimal for patients and their doctors to make informed treatment decisions using a network of electronic health records that link clinical and molecular data. To make up for hereditary susceptibilities, PM involves patients in lifestyle decisions and proactive health management [5].


PM may be able to meet the need for better health outcomes by cutting back on time, money, and healthcare expenses associated with drug development. This shift in the healthcare system will only be possible with the equal participation of patients and consumers in clinical trials, the development of smart tools and the analysis of genetic data by innovators and entrepreneurs, education of consumers and providers by regulators, understanding of diseases at the molecular level by doctors, and support from academic researchers who will work alongside innovative research projects.


  1. Klasnja P, Hekler EB, Shiffman S, et al. Microrandomized trials: An experimental design for developing just-in-time adaptive interventions. Health Psychol. 2015;34:1220.
  2. Indexed at, Google Scholar, Cross Ref

  3. Laber EB, Lizotte DJ, Qian M, et al. Dynamic treatment regimes: Technical challenges and applications. J Electron Sta. 2014;8(1):1225.
  4. Indexed at, Google Scholar, Cross Ref

  5. Chakraborty B, Murphy SA. Dynamic treatment regimes. Annu Rev Stat. 2014;1:447.
  6. Indexed at, Google Scholar, Cross Ref

  7. Wu J, Belmonte JC. Stem cells: a renaissance in human biology research. Cell. 2016;165(7):1572-85.
  8. Indexed at, Google Scholar, Cross Ref

  9. Song M, Ramakrishna S. Genome editing in stem cells for disease therapeutics. Molecular biotechnology. 2018;60(4):329-38.
  10. Indexed at, Google Scholar, Cross Ref

Get the App